AstraZeneca to Acquire 55% Ownership of Acerta for $4 Billion Total Cash Consideration $2.5 Billion to be Paid at Closing $1.5 Billion to be Paid No Later than December 2018 Option for AstraZeneca to Acquire Remaining 45% Ownership in Acerta for Up to $3 Billion OSS,...
Clinical Trial Reports a 95 Percent Response Rate in Relapsed CLL, Most Prevalent Form of Adult Leukemia Clinical Data to be Presented at ASH 2015 Annual Meeting on December 7, 2015 REDWOOD CITY , Calif. & OSS, The Netherlands;;(BUSINESS WIRE);; Acerta Pharma B.V....
Potential breakthrough therapy for treatment of autoimmune crisis Fourth arGEN-X drug candidate entering human trials in 6 years of operations Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company...
Maastricht, The Netherlands, September 29, 2015 – Cristal Therapeutics, a privately-held life sciences company developing innovative drugs against cancer and other diseases, today announced the recent start of a clinical phase I trial with its lead candidate...
Breda, The Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases,...
Strengthens Amgen’s Cardiovascular Portfolio With Late-Stage, Oral CETP Inhibitor THOUSAND OAKS, Calif. and NAARDEN, The Netherlands (Sept. 16, 2015) – Amgen (NASDAQ:AMGN) and Dezima Pharma B.V. (Dezima) today announced that the companies have entered into a...
